Enliven Therapeutics — Third Quarter 2026 Earnings Summary

Enliven Therapeutics announced alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial for relcobatinib, a small molecule kinase inhibitor for chronic myeloid leukemia, and expects to initiate the study before the end of 2026. The company reported a cash position of $884.4 million as of September 30, 2026, providing a runway into 2030, while recording a net loss of $27.7 million for the third quarter of 2026. Relcobatinib received its United States Adopted Name (USAN) designation and has demonstrated activity against BCR::ABL1 mutations, including the T315I mutation, in preclinical and Phase 1 data. Additionally, Kristine Ball was appointed to the company's Board of Directors, and management is scheduled to present at several upcoming investor conferences in November.